Louisiana State Employees Retirement System Acquires Shares of 8,000 ANI Pharmaceuticals, Inc. $ANIP

Louisiana State Employees Retirement System acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 8,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $615,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ANIP. Vanguard Group Inc. lifted its position in ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares during the period. State Street Corp boosted its holdings in ANI Pharmaceuticals by 2.2% during the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after buying an additional 15,496 shares in the last quarter. UBS Group AG grew its position in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the period. Tang Capital Management LLC lifted its position in shares of ANI Pharmaceuticals by 51.6% during the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock valued at $38,005,000 after acquiring an additional 163,937 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of ANI Pharmaceuticals by 4.2% during the 4th quarter. Geode Capital Management LLC now owns 477,272 shares of the specialty pharmaceutical company’s stock worth $37,682,000 after acquiring an additional 19,258 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Buying and Selling

In related news, SVP Ori Gutwerg sold 2,772 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total transaction of $220,374.00. Following the transaction, the senior vice president owned 78,696 shares of the company’s stock, valued at approximately $6,256,332. This represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Patrick D. Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the completion of the sale, the director directly owned 38,432 shares of the company’s stock, valued at $3,098,772.16. The trade was a 20.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 85,179 shares of company stock worth $6,720,651 in the last 90 days. 8.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ANIP has been the topic of a number of research analyst reports. Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $85.99 on Wednesday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The business’s fifty day moving average price is $81.29 and its two-hundred day moving average price is $79.47. The stock has a market cap of $1.96 billion, a PE ratio of 21.77 and a beta of 0.43. ANI Pharmaceuticals, Inc. has a one year low of $62.60 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.